Royal Bank of Canada cut shares of Zynex (NASDAQ:ZYXI – Free Report) from an outperform rating to a sector perform rating in a research report sent to investors on Wednesday, Marketbeat.com reports.

LADENBURG THALM/SH SH lowered shares of Zynex (NASDAQ:ZYXI – Free Report) from a buy rating to a neutral rating in a report released on Wednesday morning, MarketBeat.com reports. Separately, HC ...

Zynex specializes in non-invasive pain management and patient monitoring, with promising advancements. Read why I think ZYXI ...

Zynex, Inc. ( NASDAQ:ZYXI ) just released its latest full-year report and things are not looking great. It wasn't ...

Q4 2024 Earnings Call Transcript March 11, 2025 Operator: Good afternoon, ladies and gentlemen, and welcome to the Zynex ...

Zynex develops, manufactures, markets and sells medical devices used for nerve stimulation, pain management, and rehabilitation, as well as non-invasive fluid, sepsis, and laser-based pulse oximetry ...

Zynex is cutting 15% of its workforce after health insurance company Tricare temporarily suspended payments. The medical device maker said Tuesday it plans to cut jobs because Tricare has suspended ...

Zynex (ZYXI) stock drops as RBC Capital Market downgrades following the company's Q4 2024 earnings report. Read more here.

Fintel reports that on March 12, 2025, Ladenburg Thalmann downgraded their outlook for Zynex (NasdaqGS:ZYXI) from Buy to ...

Ladenburg downgraded Zynex (ZYXI) to Neutral from Buy without a price target saying the company continues to adjust operationally amid revenue ...

Shares of Zynex fell after the it said that the health insurance company Tricare--which accounts for as much as 25% of its total revenue--has temporarily suspended payments as it reviews prior claims.

Good afternoon, ladies and gentlemen, and welcome to the Zynex fourth-quarter 2024 earnings conference call. (Operator Instructions) As a reminder, this conference is being recorded. I would now like ...